Australia's most trusted
source of pharma news
Tuesday, 21 January 2025
Posted 28 March 2024 AM
Europe's advisory committee, the CHMP, has given the nod to two big drugs currently under the TGA's review at its March meeting, suggesting a similar decision will be made locally soon.
This includes Novartis' anticipated blockbuster Fabhalta also known as iptacopan for paroxysmal nocturnal haemoglobinuria (PNH) and Novo Nordisk's once-weekly basal insulin icodec called Awiqli.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.